Rexall Sundown third-quarter sales rise 41% to $43.4 mil., boosted by direct-sale business.
This article was originally published in The Tan Sheet
Executive Summary
REXALL SUNDOWN THIRD-QUARTER SALES RISE 41% TO $43.4 MIL., led by a "strong performance" by its Showcase International direct sales division, the company said in a June 29 release. Sales for Showcase International were $15.9 mil. during the quarter ended May 31, according to the firm, and represented about 37% of the company's overall business
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.